priority_rank_strict,pathway_axis,transfer_direction,falsifiable_prediction,donor_context_anchor_pmids,target_context_anchor_pmids,starter_ev_source,starter_recipient_models,primary_efficacy_endpoints,mandatory_safety_gates,minimum_ev_characterization,negative_result_falsification_rule
1,Integrin/Src,tumor_metastasis_to_cardiac_repair,"Integrin-enriched EVs will increase infarct-border uptake and improve post-MI function versus matched EV controls; blocking integrin engagement will attenuate the effect.","26524530;36800996;39329462","31815595;37237266","EPC or MSC EVs with integrin-focused engineering (e.g., ITGA6/ITGB4 enrichment)","Cardiomyocyte hypoxia-reoxygenation in vitro plus murine ischemia-reperfusion MI in vivo","Myocardial EV uptake, infarct size, LVEF/fractional shortening, capillary density","Fibrosis/EMT markers (COL1A1, ACTA2, TGFB1), pro-migratory/invasion phenotypes, endothelial barrier integrity","Particle sizing + count (NTA/TRPS), morphology (TEM/EM), EV markers (CD63/CD81/TSG101), non-EV negative marker (e.g., CALNEXIN)","No significant uptake/function gain over control or emergence of fibrosis/pro-migratory liabilities at efficacious dose."
2,Autophagy,neurodegeneration_to_cardiac_repair,"Autophagy-modulating EVs will improve cardiomyocyte survival and reduce infarct burden, with loss of benefit when autophagy flux is pharmacologically blocked.","32131688","34166712;41163081","iPSC-cardiomyocyte or MSC EVs enriched for autophagy-relevant cargo (including miR-143-3p programs)","Cardiomyocyte stress models plus murine MI or ischemia-reperfusion","LC3-II/p62 flux, apoptosis markers, infarct size, LV function","Excess autophagic flux, mitochondrial injury, maladaptive remodeling","Particle sizing + count (NTA/TRPS), morphology (TEM/EM), EV markers (CD63/CD81/TSG101), non-EV negative marker (e.g., CALNEXIN)","No improvement in survival/function, or benefit only at doses causing excessive autophagy/mitochondrial toxicity."
3,TGF-beta,tumor_metastasis_to_cardiac_repair,"Stage-timed modulation of EV-associated TGF-beta signaling will reduce adverse remodeling and fibrosis without compromising repair.","39317708","39253060;40857022;41631339","Conditioned macrophage/MSC or serum-derived EV programs with TGF-beta/Smad modulation","Murine MI remodeling timeline (acute and chronic windows) with fibrosis-focused readouts","Fibrotic area, p-Smad2/3 signaling, LV function, scar quality","Scar instability, impaired wound healing, immune suppression signatures","Particle sizing + count (NTA/TRPS), morphology (TEM/EM), EV markers (CD63/CD81/TSG101), non-EV negative marker (e.g., CALNEXIN)","No fibrosis/function benefit, or anti-fibrotic effect accompanied by impaired scar integrity or healing deficits."
4,Wnt,tumor_metastasis_to_cardiac_repair,"Transient EV-mediated Wnt tuning in early injury will improve angiogenesis and recovery, while prolonged activation will fail safety gates.","39317708","28582278;29978610;40910352","Adipose- or bone marrow MSC EVs with controlled Wnt/β-catenin activity","In vitro endothelial/cardiomyocyte assays plus rodent MI and large-animal confirmatory model","β-catenin pathway activation kinetics, angiogenesis metrics, infarct size, LV function","Hyperproliferation/tumor-like transcriptional signatures, arrhythmogenic remodeling","Particle sizing + count (NTA/TRPS), morphology (TEM/EM), EV markers (CD63/CD81/TSG101), non-EV negative marker (e.g., CALNEXIN)","No efficacy window separating benefit from proliferation/remodeling liabilities."
5,Hypoxia/HIF-1,tumor_metastasis_to_neurodegeneration,"Hypoxia-conditioned HIF-1-enriched EV programs will reduce neuronal senescence/ferroptosis and improve neurobehavioral outcomes.","37230199","40481944;40035385;41216864","Hypoxia-preconditioned NK-cell or neural stem cell EVs","Neuronal/glial stress systems plus AD/PD model cohorts with longitudinal behavior","Neuronal survival, ferroptosis/senescence markers, cognition or motor outcomes","Pro-angiogenic mispatterning, oncogenic transcriptional activation, systemic hypoxia-response overactivation","Particle sizing + count (NTA/TRPS), morphology (TEM/EM), EV markers (CD63/CD81/TSG101), non-EV negative marker (e.g., CALNEXIN)","No neuroprotection versus control or induction of pro-oncogenic/pro-angiogenic programs at active dose."
